Clinical trial
A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris in Adults With Photodynamic Therapy (PDT)
NCT05080764 is registered in ClinicalTrials.gov with Biofrontera Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris in Adults With Photodynamic Therapy (PDT)
- Lead sponsor
- Biofrontera Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 10, 2021
- Completion date
- January 7, 2026
- Enrollment
- 120 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.